Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 06, 2020 08:30 ET | Source: Kaleido Biosciences

Kaleido Biosciences to Present at the 38th Annual J.P. Morgan Healthcare Conference

LEXINGTON, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ...
December 12, 2019 08:00 ET | Source: Kaleido Biosciences

Kaleido Biosciences to Advance KB174 for Hepatic Encephalopathy Based on Positive Top-Line Results from a Clinical Study in Patients with Cirrhosis

- KB174 Exceeded the Targeted Reduction in a Biomarker of Microbiome Ammonia Production- KB174 Was Well Tolerated and No Clinically Significant or Serious Treatment-Related Adverse Events Were...
November 06, 2019 08:00 ET | Source: Kaleido Biosciences

Kaleido Biosciences Appoints William Duke as Chief Financial Officer

LEXINGTON, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ...
October 30, 2019 16:05 ET | Source: Kaleido Biosciences

Kaleido Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update

- Executing Pipeline Towards Key Clinical Data Readouts in Q4 2019 and 2020 - Focusing Resources on Pipeline Programs and Extending Cash Runway LEXINGTON, Mass., Oct. 30, 2019 (GLOBE NEWSWIRE)...
October 22, 2019 08:00 ET | Source: Kaleido Biosciences

Kaleido Biosciences and Washington University School of Medicine to Collaborate on Exploring the Influence of Microbiome Metabolic Therapies (MMT™) on Physiology and Metabolism

LEXINGTON, Mass., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ...
October 03, 2019 08:00 ET | Source: Kaleido Biosciences

Kaleido Biosciences Presents Ex Vivo Data of KB109 Demonstrating Reduction of Multi-drug Resistant Pathogens at IDWeek 2019™

Additional Presentation on Platform at Upcoming Keystone Symposia on the Microbiome: Therapeutic Implications LEXINGTON, Mass., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq:...
September 30, 2019 08:00 ET | Source: Kaleido Biosciences

Kaleido Biosciences Announces Appointment of Jean Mixer to its Board of Directors

LEXINGTON, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ...
September 26, 2019 16:10 ET | Source: Kaleido Biosciences

Kaleido Biosciences Announces CFO Transition

LEXINGTON, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ...
September 09, 2019 07:30 ET | Source: Kaleido Biosciences

Kaleido Biosciences to Collaborate with Gustave Roussy Cancer Center to Develop Microbiome Metabolic Therapies (MMT™) in Immuno-oncology

LEXINGTON, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ...
September 03, 2019 08:00 ET | Source: Kaleido Biosciences

Kaleido Biosciences Presents Data from Clinical Study of KB195 in Patients with Urea Cycle Disorders at Society for the Study of Inborn Errors of Metabolism Annual Symposium

Data Demonstrate Safety and Tolerability of Microbiome Metabolic Therapy (MMT™) Candidate KB195 and Potential for Effect on Nitrogen Metabolism, a Biomarker of Ammonia Production LEXINGTON, Mass.,...